Standards; Pharmaceutical/API Drug Impurities/Metabolites;
應(yīng)用:
Vipadenant is a potent, selective and orally available adenosine A2A receptor antagonist under development for for Parkinson's disease. Vipadenant demonstrates strong oral activity in commonly used models of Parkinson's disease. Vipadenant has shown excellent preclinical pharmacokinetics and has successfully completed phase I clinical studies.
?您的位置：
